Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Charles Darwin University, Australia
Muraglitazar requires more safety testing as a treatment for type 2 diabetes
August 18th, 2006
Muraglitazar requires more safety testing before being used as a treatment of type 2 diabetes. "Hyperglycaemia in type 2 diabetes has a major role in the development of microvascular complications, whereas the dyslipidaemia is the major cause of macrovascular complications. In patients with type 2 diabetes, activation of PPAR-alpha and PPAR-gamma with the fibrates and glitazones improves dyslipidaemia and increases insulin sensitivity, respectively," a review in Australia reports. "Muraglitazar is an agonist at both of these receptors and has been shown to increase high-density lipoprotein cholesterol, decrease triglycerides and improve insulin...
Source: Biotech Law Weekly (2006-08-18)
|
